Orient Bio

Orient Bio Equity Ratio

The Equity Ratio of Orient Bio (002630.KS) as of Oct 21, 2026 is 83.98 %. In the previous year, Equity Ratio was 84.74 % — a change of -0.90% (lower).

Equity Ratio

83.98 %

YoY

-0.90%

Last updated:

Equity Ratio of Orient Bio is 2026 83.98 % . Equity Ratio of Orient Bio was 2025 84.74 % . It decreases by -0.90% lower compared to the previous year.

The Orient Bio Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
77.05 KRW
Jan 1, 2020
72.07 KRW
Jan 1, 2021
67.88 KRW
Jan 1, 2022
79.26 KRW
Jan 1, 2023
88.08 KRW
Jan 1, 2024
87.74 KRW
Jan 1, 2025
84.74 KRW
Jan 1, 2026
83.98 KRW
The Orient Bio Equity Ratio history
YEAREquity RatioYoY
83.98 %-0.90%
84.74 %-3.41%
87.74 %-0.39%
88.08 %+11.13%
79.26 %+16.77%
67.88 %-5.81%
72.07 %-6.46%
77.05 %+177.70%
27.74 %-31.87%
40.72 %-6.93%
43.76 %+21.18%
36.11 %-8.34%
39.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Equity Ratio of Orient Bio is 83.98 % in 2026.

Equity Ratio of Orient Bio changed from 84.74 % to 83.98 %, representing a -0.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Orient Bio since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Orient Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Orient Bio

All Key Metrics — Orient Bio